Home >> BTZO 1
Related Products
BTZO 1 migration inhibitory factor (MIF) binder

Catalog No.B7614
Size Price Stock Qty
10mg
$138.00
In stock
50mg
$578.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

      

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

BTZO 1

BTZO 1 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

BTZO 1 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 99420-15-2 SDF Download SDF
Chemical Name 2-(pyridin-2-yl)-4H-benzo[e][1,3]thiazin-4-one
Canonical SMILES O=C1N=C(C2=NC=CC=C2)SC3=CC=CC=C31
Formula C13H8N2OS M.Wt 240.28
Solubility Soluble in DMSO > 10 mM Storage Store at RT
Physical Appearance Golden Yellow crystalline solid Shipping Condition Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Background

BTZO 1 binds to migration inhibitory factor (MIF) with a Kd of 68.6 nM [1].

MIF is a ubiquitous protein. It is a specific BTZO 1-binding protein. MIF is released by ischemic heart tissue. It activates the cardioprotective AMP-activated protein kinase (AMPK) pathway. MIF was reported to be a key upstream regulator of the innate and acquired immune response. MIF regulates cytokine secretion, counter-regulates glucocorticoids in inflammation, inhibits oxidative stress-induced cell death, and activates components of the Jun-activation domain-binding protein-1 (Jab-1) pathway and mitogen-activated protein kinase [1].

H9c2 cells transfected by pGL3-ARE-Luc were treated with rMIF in the presence of BTZO 1 at 1 µM. In this system, dose-dependently induced luciferase activity was found. When transfected cells were treated with rMIF alone, ARE-mediated luciferase activity was scarcely induced. Treatment with BTZO 1, also promoted rMIF induction of HO-1 mRNA and GST Ya in H9c2 cells. In H9c2 cells, pretreatment with BTZO 1 at 30 µM caused an approximately 20% decrease in tautomerase activity (measured in the cell lysate). This suggested that there was a direct interaction between MIF and BTZO 1 in H9c2 cells [1].

BTZO 2 is a BTZO 1 analog with a better ADME profile. 24 hr after reperfusion with drug, mean values for the area at risk were 46% ± 3% and 48% ± 2% for vehicle and BTZO 2, respectively. In control rats, left anterior descending coronary artery (LAD) occlusion and reperfusion caused an infarct size of 43% of the area at risk. Compared to control, intraperitoneal administration with BTZO 2 at 10 mg/kg 1 hr prior to LAD occlusion and 2 and 8 hr after reperfusion caused an approximately 45% reduction in the infarct size [1].

Reference:
[1].  Kimura H, Sato Y, Tajima Y, et al. BTZO-1, a cardioprotective agent, reveals that macrophage migration inhibitory factor regulates ARE-mediated gene expression. Chemistry & biology, 2010, 17(12): 1282-1294.